How to buy Regeneron Pharmaceuticals shares in Ireland | $599.74

Regeneron Pharmaceuticals, Inc is a biotechnology business based in the US. Regeneron Pharmaceuticals shares (REGN) are listed on the NASDAQ and all prices are listed in US Dollars. Regeneron Pharmaceuticals employs 8,314 staff and has a trailing 12-month revenue of around USD$9.2 billion.

Sponsored For

Beginners Choice

DEGIRO

Sponsored For

Low-cost Trading

eToro

Sponsored For

Overall Broker

Plus500

How to buy shares in Regeneron Pharmaceuticals from Ireland

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Regeneron Pharmaceuticals Find the stock by name or ticker symbol: REGN. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Regeneron Pharmaceuticals reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$599.74, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Regeneron Pharmaceuticals, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Regeneron Pharmaceuticals. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Compare online brokers to trade stocks, ETFs and CFDs

Warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89 % of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Sort by:

Name	Product	Number of Stocks	CFDs	Shares	Available Markets	Link
DEGIRO		Access to global markets	No	Yes	AU, AT, BE, CA, CH, CZ, DE, DK, ES, FR, FI, GR, HK, HU, IT, JP, NO, PT, PL, IE, SG, SE, TR, UK, US	Go to site More Info	Your capital is at risk.		loading Fetching your data...
eToro		2,000+	Yes	Yes	Worldwide with exception.	Go to site 71% of CFD accounts lose money More Info	CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 71% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.		loading Fetching your data...
Plus500		2,000+	Yes	Yes	US, UK, AU, DE, FR, IT, PT, GR, JP, SG, ZA, NL, FI, BE, DK, SE, CH, ES, AT, NO, HU, CZ, IE, PL, HK	Go to site 76.4% of CFD accounts lose money More Info	CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76.4% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.		loading Fetching your data...

loading

Compare up to 4 providers

Clear selection

Compare

How has coronavirus impacted Regeneron Pharmaceuticals's share price?

Since the stock market crash in March caused by coronavirus, Regeneron Pharmaceuticals's share price has had significant positive movement.

Its last market close was USD$599.74, which is 32.78% up on its pre-crash value of USD$403.15 and 76.71% up on the lowest point reached during the March crash when the shares fell as low as USD$339.39.

If you had bought USD$1,000 worth of Regeneron Pharmaceuticals shares at the start of February 2020, those shares would have been worth USD$1,335.00 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,757.24.

Regeneron Pharmaceuticals share price

Is it a good time to buy Regeneron Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Regeneron Pharmaceuticals under- or over-valued?

Valuing Regeneron Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Regeneron Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Regeneron Pharmaceuticals's P/E ratio

Regeneron Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 19x. In other words, Regeneron Pharmaceuticals shares trade at around 19x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Regeneron Pharmaceuticals's PEG ratio

Regeneron Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.9353. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Regeneron Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Regeneron Pharmaceuticals's EBITDA

Regeneron Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$3.3 billion.

The EBITDA is a measure of a Regeneron Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.

Shorting Regeneron Pharmaceuticals shares

There are currently 2.0 million Regeneron Pharmaceuticals shares held short by investors – that's known as Regeneron Pharmaceuticals's "short interest". This figure is 8% down from 2.1 million last month.

There are a few different ways that this level of interest in shorting Regeneron Pharmaceuticals shares can be evaluated.

Regeneron Pharmaceuticals's "short interest ratio" (SIR)

Regeneron Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Regeneron Pharmaceuticals shares currently shorted divided by the average quantity of Regeneron Pharmaceuticals shares traded daily (recently around 824516.80672269). Regeneron Pharmaceuticals's SIR currently stands at 2.38. In other words for every 100,000 Regeneron Pharmaceuticals shares traded daily on the market, roughly 2380 shares are currently held short.

However Regeneron Pharmaceuticals's short interest can also be evaluated against the total number of Regeneron Pharmaceuticals shares, or, against the total number of tradable Regeneron Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Regeneron Pharmaceuticals's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Regeneron Pharmaceuticals shares in existence, roughly 20 shares are currently held short) or 0.0291% of the tradable shares (for every 100,000 tradable Regeneron Pharmaceuticals shares, roughly 29 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Regeneron Pharmaceuticals.

Frequently asked questions

• What percentage of Regeneron Pharmaceuticals is owned by insiders or institutions?

  Currently 2.901% of Regeneron Pharmaceuticals shares are held by insiders and 92.166% by institutions.

• How many people work for Regeneron Pharmaceuticals?

  Latest data suggests 8,314 work at Regeneron Pharmaceuticals.

• When does the fiscal year end for Regeneron Pharmaceuticals?

  Regeneron Pharmaceuticals's fiscal year ends in December.

• Where is Regeneron Pharmaceuticals based?

  Regeneron Pharmaceuticals's address is: 777 Old Saw Mill River Road, Tarrytown, NY, United States, 10591

• What is Regeneron Pharmaceuticals's ISIN number?

  Regeneron Pharmaceuticals's international securities identification number is: US75886F1075

• What is Regeneron Pharmaceuticals's CUSIP number?

  Regeneron Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 75886F107